Lupin Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Anand Kripalu as Independent Director. The pharmaceutical company's Board of Directors had previously approved his appointment as Additional Director (Non-Executive, Independent) effective February 01, 2026, during their meeting held on January 06, 2026.

Postal Ballot Notice Details

The company issued the postal ballot notice on January 14, 2026, to stock exchanges BSE Limited and National Stock Exchange of India Limited. The notice outlines the voting process and timeline for shareholder approval:

Board Appointment Framework

Mr. Kripalu's appointment was made based on the recommendation of the Nomination and Remuneration Committee. The appointment details include:

Professional Background and Expertise

Mr. Anand Kripalu brings over three decades of extensive industry experience in the fast-moving consumer goods sector. His distinguished career includes:

• Current Role: Executive Director of EPL Limited (previously Managing Director and Global CEO until December 31, 2025)
• Previous Leadership Positions: MD & CEO of Diageo India, President of India and South-East Asia at Mondelez International (Cadbury)
• Early Career: More than 20 years at Unilever in various general management, sales and marketing roles

Educational Qualifications and Current Directorships

Mr. Kripalu holds an MBA from IIM, Calcutta, and B. Tech (Electronics) from IIT Madras. He has completed the Advanced Management Program from Wharton Business School and received Distinguished Alumnus Awards from both IIM and IIT.

He currently serves as Independent Director at:

• Swiggy Limited
• United Breweries Limited
• PGP Glass Private Limited

Voting Process and Compliance

The postal ballot will be conducted exclusively through remote e-voting facility provided by NSDL. Members whose names appear in the Register of Members as on the cut-off date of January 09, 2026, are eligible to vote. The company has appointed Mr. Saurabh Agarwal or Ms. Deepti Kulkarni from M/s. Makarand M. Joshi & Co., Practicing Company Secretaries, as Scrutinizers for the voting process.

Lupin Limited confirmed that Mr. Kripalu is not debarred from holding the office of Director by SEBI or any other authority and is not related to any Directors, Key Managerial Personnel, or Promoters of the Company.

Lupin has provided an update on its acquisition timeline for Amsterdam-based VISUfarma BV, indicating the transaction is now expected to close by February 28, 2026, subject to certain closing conditions. The pharmaceutical company had originally indicated the acquisition would be completed by the end of calendar year 2025. This development comes alongside the company's recent strategic partnership announcement for GLP-1 drug commercialization in India.

VISUfarma Acquisition Update

The company recalled that Nanomi BV, its wholly-owned subsidiary, had entered into a definitive agreement on September 29, 2025, to acquire the entire share capital of VISUfarma BV. The acquisition represents part of Lupin's broader expansion strategy, though specific financial terms and strategic rationale for the VISUfarma deal have not been disclosed.

GLP-1 Drug Partnership Reinforced

Simultaneously, Lupin has reaffirmed its exclusive licensing, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist. This strategic partnership strengthens Lupin's diabetes portfolio while expanding its presence in the obesity treatment segment for the Indian market.

Bofanglutide injection is designed for adults with type 2 diabetes and assists in weight management for overweight or obese individuals. As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that weight loss results are comparable to or better than existing GLP-1 alternatives while offering enhanced convenience through reduced injection frequency.

Market Opportunity and Health Impact

The GLP-1 partnership addresses significant health challenges in India, where obesity is anticipated to develop into a major health crisis. The market opportunity remains substantial, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes already affects approximately 90 million adults in the country, representing an epidemic-level health concern.

Current Stock Performance

Shares of Lupin ended at ₹2,080.40, declining by ₹1.70 or 0.08% during the latest trading session. The stock has faced broader challenges with a year-to-date decline of 12.00%, though the strategic partnerships in high-growth therapeutic areas are expected to draw continued investor attention.